Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15569840rdf:typepubmed:Citationlld:pubmed
pubmed-article:15569840lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:15569840lifeskim:mentionsumls-concept:C0027051lld:lifeskim
pubmed-article:15569840lifeskim:mentionsumls-concept:C0022661lld:lifeskim
pubmed-article:15569840lifeskim:mentionsumls-concept:C0403447lld:lifeskim
pubmed-article:15569840lifeskim:mentionsumls-concept:C0007222lld:lifeskim
pubmed-article:15569840lifeskim:mentionsumls-concept:C2675972lld:lifeskim
pubmed-article:15569840lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:15569840lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:15569840lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:15569840lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:15569840lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:15569840lifeskim:mentionsumls-concept:C1524081lld:lifeskim
pubmed-article:15569840lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:15569840pubmed:issue24lld:pubmed
pubmed-article:15569840pubmed:dateCreated2004-12-14lld:pubmed
pubmed-article:15569840pubmed:abstractTextPersons with end-stage renal disease and those with lesser degrees of chronic kidney disease (CKD) have an increased risk of death after myocardial infarction (MI) that is not fully explained by associated comorbidities. Future cardiovascular event rates and the relative response to therapy in persons with mild to moderate CKD are not well characterized.lld:pubmed
pubmed-article:15569840pubmed:languageenglld:pubmed
pubmed-article:15569840pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15569840pubmed:citationSubsetAIMlld:pubmed
pubmed-article:15569840pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15569840pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15569840pubmed:statusMEDLINElld:pubmed
pubmed-article:15569840pubmed:monthDeclld:pubmed
pubmed-article:15569840pubmed:issn1524-4539lld:pubmed
pubmed-article:15569840pubmed:authorpubmed-author:RouleauJean...lld:pubmed
pubmed-article:15569840pubmed:authorpubmed-author:SkaliHichamHlld:pubmed
pubmed-article:15569840pubmed:authorpubmed-author:SolomonScott...lld:pubmed
pubmed-article:15569840pubmed:authorpubmed-author:PfefferMarc...lld:pubmed
pubmed-article:15569840pubmed:authorpubmed-author:ChertowGlenn...lld:pubmed
pubmed-article:15569840pubmed:authorpubmed-author:MoyéLemuel...lld:pubmed
pubmed-article:15569840pubmed:authorpubmed-author:PackerMiltonMlld:pubmed
pubmed-article:15569840pubmed:authorpubmed-author:BraunwaldEuge...lld:pubmed
pubmed-article:15569840pubmed:authorpubmed-author:KenchaiahSati...lld:pubmed
pubmed-article:15569840pubmed:authorpubmed-author:TokmakovaMari...lld:pubmed
pubmed-article:15569840pubmed:issnTypeElectroniclld:pubmed
pubmed-article:15569840pubmed:day14lld:pubmed
pubmed-article:15569840pubmed:volume110lld:pubmed
pubmed-article:15569840pubmed:ownerNLMlld:pubmed
pubmed-article:15569840pubmed:authorsCompleteYlld:pubmed
pubmed-article:15569840pubmed:pagination3667-73lld:pubmed
pubmed-article:15569840pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:meshHeadingpubmed-meshheading:15569840...lld:pubmed
pubmed-article:15569840pubmed:year2004lld:pubmed
pubmed-article:15569840pubmed:articleTitleChronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.lld:pubmed
pubmed-article:15569840pubmed:affiliationDepartment of Cardiology, St. George Hospital, Medical University Plovdiv, Plovdiv, Bulgaria.lld:pubmed
pubmed-article:15569840pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15569840pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15569840pubmed:publicationTypeRandomized Controlled Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15569840lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15569840lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15569840lld:pubmed